A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

This is a multi-center, double-blind trial to assess the safety and efficacy of
taliglucerase alfa in untreated subjects (2 to <18 years old) with Gaucher disease randomly
assigned to treatment with one of two doses, 30 or 60 units/kg. Subjects will receive an
intravenous (IV) infusion of taliglucerase alfa every two weeks. The total duration of
treatment will be 12 months. At the end of the 12-month treatment period eligible subjects
will be offered enrollment in an open-label extension study if taliglucerase alfa is not
commercially available.